Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study

被引：0
|
作者：
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
机构：
[1] Ctr Diabet & Metab, Bad Heilbrunn, Germany
[2] Novo Nordisk Ltd, Crawley, England
[3] Inst Metab Dis & Nutr, Med Abt Stoffwechselerkrankungen & Nephrol, Vienna, Austria
[4] Triemli City Hosp, Dept Endocrinol & Diabet, Zurich, Switzerland
[5] Novo Nordisk Pharma GmbH, Dept Diabet, Mainz, Germany
[6] Univ Tubingen, Med Klin 4, Tubingen, Germany
来源：
DIABETIC MEDICINE | 2007年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    [J]. DIABETES, 2006, 55 : A460 - A461
  • [2] The PREFER study: Dosing recommendations for biphasic insulin aspart 30, insulin detemir and insulin aspart using treat-to-target titration
    Gallwitz, B.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Liebl, A.
    [J]. DIABETOLOGIA, 2006, 49 : 611 - 612
  • [3] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    [J]. DIABETES, 2006, 55 : A123 - A123
  • [4] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
    Bott, S
    Tusek, C
    Heinemann, L
    Friberg, HH
    Heise, T
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
  • [5] Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: Experience from a Dutch practice
    Ligthelm, Robert J.
    [J]. DIABETES, 2007, 56 : A540 - A540
  • [6] Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
    Fulcher, Gregory R.
    Christiansen, Jens Sandahl
    Bantwal, Ganapathi
    Polaszewska-Muszynska, Miroslawa
    Mersebach, Henriette
    Andersen, Thomas H.
    Niskanen, Leo K.
    [J]. DIABETES CARE, 2014, 37 (08) : 2084 - 2090
  • [7] Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70
    Kulesh, Victoria S.
    Drai, Roman, V
    Zinnatulina, Bella R.
    Makarenko, Igor E.
    Pilyus, Fedor G.
    Khokhlov, Alexander L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1086 - 1093
  • [8] Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects
    Hassan, Mohammad Imtiaz
    Aamir, Azizul Hasan
    Miyan, Zahid
    Siddiqui, Laiq Ahmed
    Mahmood, Shahid
    Vohra, Ejaz Ahmed
    [J]. JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (10) : 1290 - 1294
  • [9] Comparison of biphasic insulin aspart (BIAsp30) and insulin glargine (IGlarg) during isoglycaemic clamp studies in persons with type 2 diabetes
    Luzio, SD
    Peter, R
    Dunseath, GJ
    Pauvaday, V
    Owens, DR
    [J]. DIABETES, 2004, 53 : A136 - A136
  • [10] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    [J]. DIABETOLOGIA, 2018, 61 : S410 - S411
12345